Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
18.64
-1.35 (-6.75%)
Mar 12, 2026, 2:53 PM EDT - Market open

Dyne Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
69.8562.4831.428.228.72
Research & Development
398.33281.41210.76142.76121.31
Total Operating Expenses
468.18343.89242.16170.96150.03
Operating Income
-468.18-343.89-242.16-170.96-150.03
Interest Income
29.8626.927.642.920.74
Interest Expense
-6.19-0.45-1.42--
Other Non-Operating Income (Expense)
-1.7----0.01
Total Non-Operating Income (Expense)
21.9726.476.23-0.050.73
Pretax Income
-446.21-317.42-235.94-171.02-149.29
Net Income
-446.21-317.42-235.94-168.1-149.29
Net Income to Common
-446.21-317.42-235.94-168.1-149.29
Shares Outstanding (Basic)
12894605251
Shares Outstanding (Diluted)
12894605251
Shares Change (YoY)
36.43%57.74%14.83%2.13%253.54%
EPS (Basic)
-3.47-3.37-3.95-3.23-2.93
EPS (Diluted)
-3.47-3.37-3.95-3.23-2.93
Free Cash Flow
-423.92-294.75-188.89-156.71-123.18
Free Cash Flow Per Share
-3.30-3.13-3.16-3.02-2.42
EBITDA
-466.14-342.21-240.49-169.28-148.94
EBIT
-468.18-343.89-242.16-170.96-150.03
Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q